Send us a text

Navigating the complex world of workplace drug testing starts with understanding what you're actually testing for. In this illuminating conversation with Tom Fulmer, Vice President of Business Development at National Drug Screening, we unpack the sometimes confusing terminology around drug testing "panels" and what employers need to know to make informed decisions.

Did you know that a standard "5-panel" drug test can actually detect up to 13 different substances? We explore what makes up the foundation of workplace drug testing programs, from the DOT-mandated SAMHSA 5-panel to expanded options that include emerging drugs of concern like fentanyl. Tom shares his journey from having no drug testing experience to becoming the incoming president of the Substance Abuse Program Administrators Association, offering a unique perspective on how the industry has evolved.

For employers struggling with marijuana testing policies amid changing state laws, we offer practical guidance on developing compliant approaches. Whether you're operating in a single state or managing a multi-state workforce with different legal requirements, you'll learn strategies for crafting effective policies that balance safety concerns with legal compliance. We break down the differences between testing methods (lab-based vs. instant, urine vs. oral fluid vs. hair) and how panel options vary across these platforms.

Looking toward the future, we discuss SAMHSA's recent addition of fentanyl testing for federal employees, what this might mean for DOT regulations, and trends toward more customizable testing panels. Whether you're new to workplace drug testing or looking to update your current program, this episode provides the knowledge you need to select the right panels for your organization's needs. Have questions about your specific situation? Reach out to us directly at joe@nationaldrugscreening.com.